<DOC>
	<DOC>NCT00144560</DOC>
	<brief_summary>This is an open-label, clinical pharmacology study to investigate drug-drug interaction in patients with RA.</brief_summary>
	<brief_title>Drug-Drug Interaction Study of MRA in Patient With Rheumatoid Arthritis (RA)</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Inclusion criteria Patients who are diagnosed with RA according to the 1987 American College of Rheumatology (ACR) classification criteria Patients who contracted RA at least 6 months prior Exclusion criteria Patients with Class IV Steinbrocker functional impairment at enrollment. Patients who have been treated for the underlying disease with a biological agent, such as infliximab or etanercept and have been receiving treatment with leflunomide, within 12 weeks before initiation of treatment with the probe drug</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2008</verification_date>
</DOC>